Biotin-LC Alpha-Synuclein (91-110) Peptide

Product Name
Biotin-LC Alpha-Synuclein (91-110) Peptide
Product Quantity
4 mg
Catalog Number
LT8709
Sequence
ATGFVKKDQLGKNEEGAPQE
Ala-Thr-Gly-Phe-Val-Lys-Lys-Asp-Gln-Leu-Gly-Lys-Asn-Glu-Glu-Gly-Ala-Pro-Gln-Glu
Purity
>95%
Modifications
LCbiot, 1mg/vial
Peptide Type
Human alpha-synuclein research fragment
Scientific Background

Past residue 95 alpha-synuclein changes character entirely. The C-terminal third is strongly acidic, stays disordered even within mature fibrils, and acts to keep the protein soluble rather than to drive assembly. This peptide covers residues 91 to 110, spanning the end of the aggregation core and the start of that tail.

Removing the tail accelerates aggregation. C-terminal truncation is observed in pathological material and is understood to act by stripping away the solubilising region, so truncated and full-length species behave differently and are distinguished in disease studies. The region also carries the principal post-translational modification sites associated with pathology and is where several widely used antibodies bind.

That gives this peptide a specific diagnostic use: establishing whether an antibody requires the intact C-terminus, and therefore whether it will detect truncated species at all. A reagent that fails against this peptide but succeeds against full-length protein is reading something else. Note that the stretch between this peptide and the one ending at residue 70 is not covered by this series, so an antibody negative across the whole set may bind an uncovered window rather than a conformational epitope.

Research Applications
  • C-terminal truncation studies and their effect on solubility
  • Validating antibodies that require an intact acidic C-terminus
  • Post-translational modification site mapping
  • Distinguishing truncated from full-length species in patient samples
  • C-terminal anchor point of the overlapping peptide walk
References

1. Initiation and progression of alpha-synuclein pathology in Parkinson's disease. Cellular and Molecular Life Sciences (2022). CMLS 2022

2. The Parkinson disease gene SNCA: evolutionary and structural insights with pathological implication. Scientific Reports (2016). Sci Rep 2016

3. Autoantibodies against alpha-synuclein inhibit its aggregation and cytotoxicity. Anti-synuclein autoantibodies

  • 1 Units in Stock
Ask a Question

Add to Cart: